GlassScriptPhysician profile
Martha Mefferd
NPI 1013296201
$4,540.33
in general payments reported to CMS, 2019-2025
19 companies · $1,712 in 2025
The $1,712 reported for 2025 was more than what 90% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $149 · 2022: $136 · 2023: $377 · 2024: $2,166 · 2025: $1,712.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,245 · Education: $10.33.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,245.11 |
| Education | $10.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $772.64 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $698.23 | 2021-2025 | Rexulti |
| Alkermes, INC. | $595.21 | 2021-2025 | Aristada, Lybalvi |
| Janssen Pharmaceuticals, INC | $481.89 | 2022-2025 | Spravato, Invega Sustenna |
| Lundbeck LLC | $416.50 | 2023-2025 | Rexulti |
| Corium, LLC | $358.21 | 2023-2025 | Azstarys |
| Takeda Pharmaceuticals U.S.A., INC. | $207.11 | 2024-2025 | Trintellix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $149.63 | 2024-2025 | Caplyta |
| Supernus Pharmaceuticals, INC. | $143.82 | 2024-2025 | Qelbree |
| Axsome Therapeutics, INC. | $133.65 | 2023-2025 | Auvelity |
| Lilly USA, LLC | $119.42 | 2025 | Zepbound |
| Biogen, INC. | $118.86 | 2024-2025 | Zurzuvae |
| Noven Therapeutics, LLC | $95.30 | 2024-2025 | Xelstrym |
| Collegium Pharmaceutical, INC. | $73.19 | 2025 | Jornay Pm |
| Neurocrine Biosciences, INC. | $53.37 | 2024 | Ingrezza |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $49.34 | 2023-2024 | Uzedy, Austedo Xr |
| E.R. Squibb & Sons, L.L.C. | $40.06 | 2024-2025 | Cobenfy |
| Vanda Pharmaceuticals INC. | $20.09 | 2024 | Fanapt |
| Ironshore Pharmaceuticals INC. | $13.81 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Martha Mefferd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.